Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.59K Buy
30
+7
+30% +$582 ﹤0.01% 929
2026
Q2
$1.55K Sell
23
-5
-18% -$333 ﹤0.01% 1011
2026
Q1
$1.76K Buy
28
+8
+40% +$557 ﹤0.01% 923
2025
Q4
$1.33K Sell
20
-107
-84% -$6.92K ﹤0.01% 1064
2025
Q3
$8.55K Sell
127
-91
-42% -$7.2K ﹤0.01% 684
2025
Q2
$19K Sell
218
-60
-22% -$4.7K ﹤0.01% 664
2025
Q1
$19K Buy
278
+150
+117% +$12.2K ﹤0.01% 701
2024
Q4
$10K Buy
128
+101
+374% +$7.48K ﹤0.01% 498
2024
Q3
$1.81K Hold
27
– – ﹤0.01% 571
2024
Q2
$3.06K Sell
27
-564
-95% -$71.3K ﹤0.01% 570
2024
Q1
$82K Buy
+591
New +$74.3K 0.01% 328
2023
Q4
– Sell
-15
Closed -$1.4K – 616
2023
Q3
$1.4K Buy
+15
New +$1.69K ﹤0.01% 584

Other funds holding DXCM

SouthState's DXCM Position: Q3 2026 in Review

SouthState increased its DexCom (DXCM) stake by 30% in Q3 2026, buying an estimated $582 and bringing the position to 30 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #929.

SouthState first reported a position in DXCM in Q3 2023 and has held it in 12 quarters since. The position peaked at $82K in Q1 2024. 868 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • SouthState held 30 shares of DexCom worth $2.59K as of Q3 2026.
  • SouthState bought 7 DexCom shares in Q3 2026, an estimated $582.
  • DexCom made up ﹤0.01% of SouthState's portfolio in Q3 2026, its #929 holding.
  • SouthState first reported a position in DexCom in Q3 2023 and has held it in 12 quarters since.
  • SouthState's DexCom position peaked at $82K in Q1 2024.
  • 868 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on SouthState's 13F filing for Q3 2026, filed 9 Nov 2026.